journal article·2021-04-12Open access

Antimicrobial Peptide-Functionalized Mesoporous Hydrogels

Saba Atefyekta, Edvin Blomstrand, Anand K. Rajasekharan, Sara Svensson, Margarita Trobos, Jaan Hong, Thomas J. Webster, Peter Thomsen, Martin Andersson

Abstract

Antimicrobial peptides (AMPs) are seen as a promising replacement to conventional antibiotics for the prevention of skin wound infections. However, due to the short half-life of AMPs in biological environments, such as blood, their use in clinical applications has been limited. The covalent immobilization of AMPs onto suitable substrates is an effective solution to create contact-killing surfaces with increased long-term stability. In this work, an antimicrobial peptide, RRPRPRPRPWWWW-NH2 (RRP9W4N), was covalently attached to amphiphilic and ordered mesoporous Pluronic F127 hydrogels made of cross-linked lyotropic liquid crystals through 1-ethyl-3-(3-(dimethylamino)propyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS) chemistry. The AMP-hydrogels showed high antibacterial activity against Staphylococcus epidermidis, Staphylococcus aureus, Pseudomonas aeruginosa, methicillin-resistant S. aureus (MRSA), and multidrug-resistant Escherichia coli for up to 24 h. Furthermore, the AMP-hydrogels did not present any toxicity to human fibroblasts. The AMPs retained their antimicrobial activity up to 48 h in human blood serum, which is a significant increase in stability compared to when used in dissolved state. A pilot in vivo rat model showed 10-100× less viable counts of S. aureus on AMP-hydrogels compared with control hydrogels during the first 3 days of infection. Studies performed on human whole blood showed that blood coagulated more readily in the presence of AMP-hydrogels as compared to hydrogels without AMPs, indicating potential hemostatic activity. Overall, the results suggest that the combination of amphiphilic hydrogels with covalently bonded AMPs has potential to be used as antibacterial wound dressing material to reduce infections and promote hemostatic activity as an alternative to antibiotics or other antimicrobial agents, whose use should be restricted.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Antimicrobial Peptides and Activities · Wound Healing and Treatments · Antimicrobial agents and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden

Department of Biomaterials, Sahlgrenska Academy at University of Gothenburg, Box 412, SE-405 30 Gothenburg, Sweden

Center for Antibiotic Resistance Research (CARe), University of Gothenburg, SE-40530 Gothenburg, Sweden

Department of Immunology, Genetic and Pathology, Uppsala University, Rudbeck Laboratory C5, 75185 Uppsala, Sweden

Department of Chemical Engineering, Northeastern University, Boston, Massachusetts 02115, United States

Funding

Stiftelsen Handlanden Hjalmar Svenssons · Adlerbertska Stiftelserna · Doktor Felix Neuberghs Stiftelse · IngaBritt och Arne Lundbergs Forskningsstiftelse · Knut och Alice Wallenbergs Stiftelse · Nanoscience and Nanotechnology Area of Advance, Chalmers Tekniska H?gskola

References (54)

Show source-provided references
1. 10.3390/molecules2309239210.3390/molecules23092392 ↗
2. 10.1053/ic.1998.v26.a9352710.1053/ic.1998.v26.a93527 ↗
3. 10.1097/00044067-200208000-0000510.1097/00044067-200208000-00005 ↗
4. Gürgen M. · Ewma J. · 2014 · 14 · 17
5. 10.1093/jac/dkh51310.1093/jac/dkh513 ↗
6. 10.1099/mic.0.028712-010.1099/mic.0.028712-0 ↗
7. 10.1111/j.1524-475X.2007.00283.x10.1111/j.1524-475X.2007.00283.x ↗
8. Meara S. O. · Health Technol. Assess. · 2000 · 4 · 1
9. 10.1016/S0140-6736(15)00729-110.1016/S0140-6736(15)00729-1 ↗
10. 10.1126/science.257.5073.105010.1126/science.257.5073.1050 ↗
11. 10.1016/0002-9343(93)90147-H10.1016/0002-9343(93)90147-H ↗
12. 10.1007/s10295-006-0139-710.1007/s10295-006-0139-7 ↗
13. Angel, D.; Swanson, T.; Sussman, G.; Shultz, G.; Ousey, K.; Keast, D.; Fletcher, J.; Cooper, R.; Carville, K.; Call, E.; Black, V.; Haesler, V. Wound Infection in Clinical Practice. International Wound Infection Institute (IVVII), Wound International, 2016.
14. 10.1038/s41565-017-0013-y10.1038/s41565-017-0013-y ↗
15. 10.1128/CMR.14.2.244-269.200110.1128/CMR.14.2.244-269.2001 ↗
16. Orsted H. L. · 2017
17. 10.1038/415389a10.1038/415389a ↗
18. 10.1016/j.peptides.2003.09.01310.1016/j.peptides.2003.09.013 ↗
19. Nizet V. · Curr. Issues Mol. Biol. · 2006 · 8 · 11
20. Mor A. · 2001 · 1
21. 10.1111/exd.1292910.1111/exd.12929 ↗
22. 10.1016/j.jss.2007.12.75410.1016/j.jss.2007.12.754 ↗
23. 10.1086/59318510.1086/593185 ↗
24. Björn, C. Antimicrobial peptides in the treatment of infectious and inflammatory conditions Preclinical studies of mechanism of action, efficacy, and safety. Doctoral thesis, Sahlgrenska Academy, 2016; http://hdl.handle.net/2077/44863.
25. 10.1021/bi701990410.1021/bi7019904 ↗
26. 10.1371/journal.pone.001268410.1371/journal.pone.0012684 ↗
27. 10.1016/S0092-8674(00)81895-410.1016/S0092-8674(00)81895-4 ↗
28. 10.1007/s00726-005-0289-310.1007/s00726-005-0289-3 ↗
29. 10.1016/j.actbio.2010.11.00510.1016/j.actbio.2010.11.005 ↗
30. 10.1016/j.actbio.2013.09.00910.1016/j.actbio.2013.09.009 ↗
31. 10.1080/0892701090295420710.1080/08927010902954207 ↗
32. 10.1016/j.biomaterials.2009.03.02510.1016/j.biomaterials.2009.03.025 ↗
33. 10.1111/j.1365-2672.2008.03942.x10.1111/j.1365-2672.2008.03942.x ↗
34. 10.1128/AAC.39.2.30110.1128/AAC.39.2.301 ↗
35. 10.1002/adma.20140492610.1002/adma.201404926 ↗
36. 10.1021/jp973029710.1021/jp9730297 ↗
37. 10.1016/j.ejpb.2018.11.00910.1016/j.ejpb.2018.11.009 ↗
38. 10.1016/j.burns.2012.04.00710.1016/j.burns.2012.04.007 ↗
39. 10.3390/ma808515410.3390/ma8085154 ↗
40. 10.1016/j.biotechadv.2011.01.00510.1016/j.biotechadv.2011.01.005 ↗
41. 10.1021/acs.cgd.5b0013910.1021/acs.cgd.5b00139 ↗
42. 10.1016/j.bbamem.2006.04.00610.1016/j.bbamem.2006.04.006 ↗
43. 10.1016/j.actbio.2018.10.03910.1016/j.actbio.2018.10.039 ↗
44. 10.1002/smll.20170055010.1002/smll.201700550 ↗
45. 10.1128/AAC.00300-1010.1128/AAC.00300-10 ↗
46. 10.1016/j.biomaterials.2014.11.03210.1016/j.biomaterials.2014.11.032 ↗
47. 10.1155/2015/65203510.1155/2015/652035 ↗
48. Mekaj Y. H. · Int. J. Clin. Exp. Med. · 2016 · 9 · 5347
49. 10.1021/acs.chemmater.9b0085010.1021/acs.chemmater.9b00850 ↗
50. 10.1039/C6TB00330C10.1039/C6TB00330C ↗
51. 10.1016/j.eurpolymj.2018.12.01910.1016/j.eurpolymj.2018.12.019 ↗
52. 10.1371/journal.pone.001268410.1371/journal.pone.0012684 ↗
53. 10.1016/j.carbpol.2018.08.03010.1016/j.carbpol.2018.08.030 ↗
54. 10.1016/j.actbio.2013.03.03310.1016/j.actbio.2013.03.033 ↗